HealthDay on MSN28 分钟
Speed of Resuscitation Critical to Survival Outcomes After Cardiac Arrest Events
For patients with out-of-hospital cardiac arrest (OHCA), the proportion receiving layperson bystander life support (BLS) has ...
An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
PharmiWeb28 分钟
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for ...
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...